Serum heat-shock protein-65 antibody levels are elevated but not associated with disease activity in patients with rheumatoid arthritis and ankylosing spondylitis

Heat-shock proteins (HSPs) have gained increased interest for their role in autoimmune disorders. These proteins are targeted by the immune system in various autoimmune diseases. The aim of this study was to assess the serum heat-shock protein-65 antibody (anti-HSP65) levels and their clinical signi...

Full description

Saved in:
Bibliographic Details
Published in:Open access rheumatology: research and reviews 2018-01, Vol.10, p.55-60
Main Authors: Ulusoy, Hasan, Akgol, Gurkan, Gulkesen, Arif, Kaya, Arzu, Ayden Kal, Gul, Kaman, Dilara, Tuncer, Turkan
Format: Article
Language:English
Subjects:
Age
Ankylosing spondylitis
Antibodies
Antigens
Arthritis
Autoimmune diseases
B cells
Biochemistry
Care and treatment
Cytokines
Enzyme-linked immunosorbent assay
Health risk assessment
Heat shock protein
Heat shock proteins
HSP
Immune system
Immunoglobulins
Immunology
Immunotherapy
Laboratories
Medical research
Original Research
Peptides
Proteins
Questionnaires
Rheumatoid arthritis
Rheumatoid factor
Rheumatology
Shock
Spondylitis
Studies
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Heat-shock proteins (HSPs) have gained increased interest for their role in autoimmune disorders. These proteins are targeted by the immune system in various autoimmune diseases. The aim of this study was to assess the serum heat-shock protein-65 antibody (anti-HSP65) levels and their clinical significance in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). A total of 30 patients with RA, 30 patients with AS, and 30 healthy controls were enrolled in this study. All patients were assessed using routine clinical and laboratory evaluations. Serum anti-HSP65 levels were determined by ELISA. Serum anti-HSP65 levels of both RA and AS patients were significantly higher than those of controls ( =0.014 and =0.001, respectively). No association was found between serum anti-HSP65 levels and disease activity in either RA or AS patients. There was a significant correlation between anti-HSP65 and anti-cyclic citrullinated peptide levels in patients with RA ( =0.024). In this study, serum anti-HSP65 levels were increased, but not associated with disease activity in both RA and AS patients. These results suggest that HSP antigens may play a role in the pathogenesis. However, further follow-up studies are needed. Identification of target antigens such as HSP65 is vital to developing new immunotherapeutic agents.
ISSN:1179-156X
1179-156X
DOI:10.2147/OARRR.S162512